Eugene, Completion of Phase 2a Clinical Trials for Two COVID-19 Vaccines in Australia

Bio-pharmaceutical company iGene announced on the 28th that it has completed dosing participants in the booster clinical Phase 2a trial of two messenger ribonucleic acid (mRNA)-based COVID-19 vaccines being conducted in Australia.

Since June, iGene has been conducting clinical trials in Australia for the mRNA-based COVID-19 vaccine 'EG-COVID' and the Omicron variant vaccine 'EG-COVARo'.

In the Phase 2a clinical trial, EG-COVID and EG-COVARo were administered to 46 healthy adults who had previously received authorized COVID-19 preventive vaccines. Through this, the plan is to evaluate immunogenicity by measuring tolerability and changes in antibody levels.

Regarding this, an iGene official explained, "Starting with the development of the COVID-19 mRNA vaccine, our goal is to demonstrate the in vivo efficacy of the mRNA-based platform technology 'EG-R' (EG-Ral) system, which features a cationic liposome delivery structure developed with our proprietary technology." They added, "Since we have already confirmed that mRNA-based COVID-19 vaccines such as EG-COVID have no adverse effects and are safe in humans, the purpose of this clinical trial is to verify safety with high-dose administration and to determine the optimal dosage."

Meanwhile, iGene is planning a Phase 1/2a booster shot trial for 'EG-COVII', an mRNA COVID-19 multivalent vaccine currently under development in Australia.